KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) EBT Margin (2016 - 2025)

Teva Pharmaceutical Industries' EBT Margin history spans 10 years, with the latest figure at 1.7% for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 1022.0% year-over-year to 1.7%, compared with a TTM value of 7.09% through Dec 2025, up 1553.0%, and an annual FY2025 reading of 7.09%, up 1485.0% over the prior year.
  • EBT Margin for Q4 2025 was 1.7% at Teva Pharmaceutical Industries, down from 14.42% in the prior quarter.
  • The five-year high for EBT Margin was 14.42% in Q3 2025, with the low at 31.11% in Q2 2022.
  • Average EBT Margin over 5 years is 4.51%, with a median of 1.3% recorded in 2021.
  • Year-over-year, EBT Margin soared 12192bps in 2021 and then plummeted -3899bps in 2022.
  • Tracing TEVA's EBT Margin over 5 years: stood at 4.27% in 2021, then crashed by -615bps to 30.51% in 2022, then skyrocketed by 137bps to 11.38% in 2023, then crashed by -175bps to 8.52% in 2024, then skyrocketed by 120bps to 1.7% in 2025.
  • Per Business Quant, the three most recent readings for TEVA's EBT Margin are 1.7% (Q4 2025), 14.42% (Q3 2025), and 4.86% (Q2 2025).